Esophageal carcinoma is an aggressive malignancy with multifactorial etiology. Preoperative chemo/chemoradiotherapy followed by surgery currently represents the standard approach to locally advanced esophageal carcinoma. Assessment of tumor response to neoadjuvant treatment is best done by histopathological examination of the resected specimen of esophageal carcinoma. Aim of the study is macroscopic and microscopic evaluation of the esophageal carcinomas following neoadjuvant chemo/chemoradiotherapy in the neoplastic and adjacent non neoplastic tissue. Lymph nodes were evaluated for similar features. Also evaluation of tumor regression was done using Becker’s grading system. It is a prospective and retrospective observational study of fifty esophageal carcinoma cases (including carcinoma of gastro esophageal junction). In the diagnosed cases of esophageal carcinomas full clinical information and relevant radiological findings were noted down. Clinicopathological variables were evaluated for their relationship with tumor regression status. Gross findings of the surgically resected specimens and microscopic findings for various therapy related changes were noted down.  There were 18 males and 32 females (M: F:: 0. 56 : 1  ) with age ranging from 25 yrs to 70 yrs (median age is 48 yrs).Squamous cell carcinoma  and adenocarcinoma were 37 and 11 cases respectively besides single case of high grade neuroendocrine tumor and  adenosquamous carcinoma each. 40 % cases achieved complete tumor regression. Histological grading of post chemotherapy specimens were compared with the initial biopsy. Tumor response to neoadjuvant treatment is prognostically significant as described in many studies. Therefore it can be concluded that response to neoadjuvant therapy can be evaluated by histopathological examination of the resected specimen of esophageal carcinoma. Proper macroscopic and microscopic evaluation of such specimens are difficult and challenging task especially in cases of examination of specimens of esophageal carcinoma with good response to chemo/chemoradiation.

1. Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol. 2010;16(30):3793-803.doi: 10.3748/wjg.v16.i30.3793, PMID 20698042.
2. Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, Schaefer H, Thiele J, Dienes HP, Mueller RP, Hoelscher AH. Histomorphologic tumor regression and lymph node metastases determine prognosis following Neoadjuvant Radio chemotherapy for esophageal cancer. Ann Surg. 2005;242(5):684-92. doi: 10.1097/01.sla.0000186170.38348.7b, PMID 16244542.
3. Enzinger PC, Mayer RJ. Esophageal Cancer. N Engl J Med. 2003;349(23):2241-52. doi: 10.1056/NEJMra035010, PMID 14657432.
4. Aaltonen L, Hamilton S. World Health Organization Classification of Tumours, Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000.
5. Ilson DH. Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res. 2008 Mar–Apr;2(2):85-92. PMID 19259300.
6. Kumar V, Abbas A. haryana: ElsvierInc. Aster j. Robbins and CotranPatholoic basis of disease. 9th ed. 2015.
7. Halperin E, Wazer D, Brady L, Perez C. Perez and Brady’s principles and practice of radiation oncology. 6th ed; 2013.
8. Thies S, Langer R. Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol. 2013;3:262. doi: 10.3389/fonc.2013.00262, PMID 24109590.
9. Chang F, Deere H, Mahadeva U, George S. Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues. Am J Clin Pathol. 2008;129(2):252-62. doi: 10.1309/CCR3QN4874YJDJJ7, PMID 18208806.
10. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521-30. doi: 10.1002/cncr.11660. PMID 14508841.
11. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680-6. doi: 10.1002/1097-0142(19940601)73:11<2680::aid-cncr2820731105>3.0.co;2-c, PMID 8194005.
12. Mirza A, Naveed A, Hayes S, Formela L, Welch I, West CM, Pritchard S. Assessment of Histopathological Response in Gastric and gastro-oesophageal junction adenocarcinoma following neoadjuvant Chemotherapy: which Scoring System to Use? ISRN Pathol. 2012;2012:1-8. doi: 10.5402/2012/519351.
13. Schmidt T, Sicic L, Blank S, Becker K, Weichert W, Bruckner T, Parakonthun T, Langer R, Büchler MW, Siewert JR, Lordick F, Ott K. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer. 2014;110(7):1712-20. doi: 10.1038/bjc.2014.94, PMID 24569472.
14. Noble F, Nolan L, Bateman AC, Byrne JP, Kelly JJ, Bailey IS, Sharland DM, Rees CN, Iveson TJ, Underwood TJ, Bateman AR. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World J Gastroenterol. 2013;19(48):9282-93. doi: 10.3748/wjg.v19.i48.9282, PMID 24409055.
15. Ressiot E, Dahan L, Liprandi A, Giorgi R, Djourno XB, Padovani L, Alibert S, Ries P, Laquière A, Laugier R, Thomas P, Seitz JF. Predictive factors of the response to chemoradiotherapy in esophageal cancer. Gastroenterol Clin Biol. 2008;32(6-7):567-77. doi: 10.1016/j.gcb.2008.02.033, PMID 18555630.
16. Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O’Byrne K, Kennedy J, Murphy TJ. Long-term outcomes following Neoadjuvant Chemoradiotherapy for esophageal cancer. Ann Surg. 2007;245(5):707-16. doi: 10.1097/01.sla.0000254367.15810.38, PMID 17457163.
17. Chao YK, Chang CB, Chuang WY, Wen YW, Chang HK, Tseng CK, Yeh CJ, Liu YH. Correlation between tumor regression grade and clinicopathological parameters in patients with squamous cell carcinoma of the esophagus who received Neoadjuvant Chemoradiotherapy. Medicine. 2015;94(34):e1407.doi: 10.1097/MD.0000000000001407
18. Sethi D, Sen R, Parshad S, Khetarpal S, Garg M, Sen J. Histopathologic changes following neoadjuvant chemotherapy in various malignancies. Int J Appl Basic Med Res. 2012;2(2):111-6. doi: 10.4103/2229-516X.106353, PMID 23776823.
19. Bollschweiler E, Metzger R, Drebber U, Baldus S, Vallböhmer D, Kocher M, Hölscher AH. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 2009;20(2):231-8. doi: 10.1093/annonc/mdn622. PMID 18836090.
20. Witmer L. Clinical anatomy and histology of the upper gastrointestinal system. Athens: College of Osteopathic Medicine Ohio University; 2003.
21. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005; 103(7):1347-55. doi: 10.1002/cncr.20916, PMID 15719440.
22. Rosai J. Rosai and Ackerman’s Surgical Pathology 10e. London: Elsevier Health Sciences; 2011.
23. Shapiro J, van Hagen P, Lingsma HF, Wijnhoven BP, Biermann K, ten Kate FJ, Steyerberg EW, van der Gaast A, van Lanschot JJ, CROSS Study Group. Prolonged time to surgery after Neoadjuvant Chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer. Ann Surg. 2014;260(5):807-13; discussion 813. doi: 10.1097/SLA.0000000000000966, PMID 25379852.
24. American College of Gastroenterology (ACG). Type 2 diabetes may increase the risk of Barrett’s esophagusLas Vegas, NV; Oct 22, 2012.
25. Tong DK, Law S, Kwong DL, Chan KW, Lam AK, Wong KH. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol. 2010;17(8):2184-92. doi: 10.1245/s10434-010-0995-2, PMID 20217248.
26. Dunne B, Reynolds JV, Mulligan E, Kelly A, Griffin M. A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. J Clin Pathol. 2001;54(11):841-5. doi: 10.1136/jcp.54.11.841, PMID 11684717.
27. Langer R, Ott K, Feith M, Lordick F, Siewert JR, Becker K. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol. 2009;22(12):1555-63. doi: 10.1038/modpathol.2009.123, PMID 19801967.
28. Lorenzen S, Thuss-Patience P, Al-Batran SE, Lordick F, Haller B, Schuster T, Pauligk C, Luley K, Bichev D, Schumacher G, Homann N. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol. 2013;24(8):2068-73. doi: 10.1093/annonc/mdt141, PMID 23592699.
29. Ordu A, Nieder C, Geititz H, Scherer V, Kup P. et al. Association between Radiation Dose and Pathological Complete Response after preoperative radiochemotherapy in Esophageal squamous Cell Cancer. anti cancer research. 2014;34(12):7255-61.
30. Guo K, Cai L, Zhang Y, Zhu JF, Rong TH, Lin P, Hao CL, Wang WP, Li Z, Zhang LJ. The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy. Chin J Cancer. 2012;31(8):399-408. doi: 10.5732/cjc.011.10406, PMID 22572013.
31. Beasley P. Anatomy of the pharynx and esophagus. In: Kerr AG, Gleeson M, editors Scott-brown’s otolaryngology. 6th ed. Oxford, UK: Butterworth-Heinemann; 1997.
32. Darnton SJ, Allen SM, Edwards CW, Matthews HR. Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy. J Clin Pathol. 1993;46(1):51-5. doi: 10.1136/jcp.46.1.51, PMID 8432889.
33. Postma GN, Seybt MW, Rees CJ. Esophagology. In: Snow JB, Wackym PA, editors Ballinger’s otolaryngology Head & neck surgery. 17th ed. Shelton, CT: B C Decker Inc; 2009. p. 975-95.
34. R, Lundgren L, Förnvik D, Engelholm S. High?dose rate intraluminal brachytherapy for oesophageal cancer using MR imaging: A clinical implementation [Master of Science thesis] VT2015.
35. Karamitopoulou E, Thies S, Zlobec I, Ott K, Feith M, Slotta-Huspenina J, Lordick F, Becker K, Langer R. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches. Am J Surg Pathol. 2014;38(11):1551-6. doi: 10.1097/PAS.0000000000000255, PMID 25140894.
36. Gray H Chapter 35. Mediastinum. In: Standring S, editor Gray’s anatomy: the anatomical basis of clinical practice. 41st ed. New York: Churchill Livingstone Elsevier; 2008. p. 939-57.
37. Brücher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, Busch R, Zimmermann F, Molls M, Höfler H, Siewert JR. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer. 2006;106(10):2119-27. doi: 10.1002/cncr.21850, PMID 16607651.
38. Van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WM, van Dekken H, Tran TC, van der Gaast A. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer. 2006;94(10):1389-94. doi: 10.1038/sj.bjc.6603134, PMID 16670722.
39. Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, Friess H, Hofler H. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253(5):934-9. doi: 10.1097/SLA.0b013e318216f449, PMID 21490451.
40. Washington K, Berlin J, Branton P, Burgart L. Protocol for the examination of specimens from patients with carcinoma of the esophagus. College Of American Pathologist; 2013;:Esophagus 3.1.1.2.
41. Edge SB, Byrd DR, Carducci MA, Compton CC, eds. AJCC cancer staging manual. 7th ed. New York: Springer; 2009p. p. 103-5.
42. Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO classification of tumours of the digestive system. Geneva, Switzerland: WHO Press; 2010.
43. Su M, Lu SM, Tian DP, Zhao H, Li XY, Li DR, Zheng ZC. Relationship between ABO blood groups and carcinoma of esophagus and cardia in Chaoshan inhabitants of China. World J Gastroenterol. 2001;7(5):657-61. doi: 10.3748/wjg.v7.i5.657, PMID 11819849.
44. Wang W, Liu L, Wang Z, Wei M, He Q, Ling T, Cao Z, Zhang Y, Wang Q, Shi M. Impact of ABO blood group on the prognosis of patients undergoing surgery for esophageal cancer. BMC Surg. 2015;15(1):106. doi: 10.1186/s12893-015-0094-1, PMID 26420728.
45. Kumar N, Kapoor A, Kalwar A, Narayan S, Singhal MK, Kumar A, Mewara A, Bardia MR. Allele frequency of ABO Blood Group Antigen and the Risk of Esophageal Cancer. BioMed Res Int. 2014;2014:Article ID 286810. doi: 10.1155/2014/286810, PMID 25054136.
46. Daly JM, Fry WA, Little AG, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg. 2000;190:562-72.
47. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor typeis an independent prognostic parameter in esophageal cancer: lessons from more than1,000 consecutive resections at a single center in the Western world. Ann Surg. 2001;234(3):360-7; discussion 368. doi: 10.1097/00000658-200109000-00010